$FSCO

FS Credit Opportunities Corp. (FSCO) Declares Distribution for June 2026

FS Credit Opportunities Corp. (NYSE: FSCO) said its board declared a monthly cash distribution of $0.0583 per share for June 2026, payable June 30, 2026. The company stated the distribution has been fully covered by net investment income on a tax basis through 2026 and cited YTD estimated returns of 2.8% (NAV) and -15.0% (market price) through May 31, 2026.

Original reporting
Published Jun 9, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 9, 2026, 9:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
FS Credit Opportunities Corp. (FSCO) Declares Distribution for June 2026 — source image
Decision brief

The 30-second read

$FSCOBullishLow
01

Why it matters

The key new tradable datapoint is the declared per-share distribution and its stated coverage, which can influence yield-demand and short-term positioning around the ex-date/payment cycle.

02

Market read

For income/CEF traders, the distribution declaration can affect near-term demand, but the release lacks new guidance or portfolio-specific catalysts.

03

What to watch

Traders may focus more on ex-dividend timing, NAV discount/premium, and any upcoming changes in portfolio credit risk than on the headline payout amount alone.

Relevance 5/10Novelty 5/10Timing: Distribution payable June 30, 2026

Background

FS Credit Opportunities Corp. is a closed-end fund paying regular monthly cash distributions; this PRNewswire release announces the June 2026 payout and payment schedule.

Company-level read

Ticker impact

$FSCOBullishMedium confidence
Context

FS Credit Opportunities Corp. declared a $0.0583/share monthly distribution payable June 30, 2026, with coverage by net investment income in 2026.

Expected impact

Near-term: modest support around income expectations; limited upside unless the market re-prices distribution sustainability.

Evidence & confidence

The article discloses a specific cash distribution amount and payment date plus “fully covered” language, but provides no new portfolio performance, NAV change, or forward distribution guidance beyond the monthly schedule.

Market effects

Reinforces that event-driven/special-situations credit CEFs are maintaining monthly payout cadence and claiming coverage.

None material beyond US closed-end fund income flows.

Limited; primarily affects US income/CEF investor sentiment.

Counterpoint

“Fully covered” is on a tax basis and may not reflect economic earnings quality; distribution could still be vulnerable if credit conditions worsen.

Key entities

  • FS Credit Opportunities Corp.

    Closed-end fund declaring a $0.0583/share monthly distribution for June 2026, payable June 30, 2026.

  • Future Standard

    Alternative asset manager referenced in the release’s “About” section.

Related articles

$FSCOLow

FSCO Announces Earnings Release and Conference Call Schedule for Second Quarter 2026

FS Credit Opportunities Corp. (FSCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FSCO Announces Earnings Release and Conference Call Schedule for Second Quarter 2026 PHILADELPHIA, August 5, 2026 -- FS Credit Opportunities Corp. (NYSE: FSCO) today announced that it will release its financial results for the second quarter ended June 30, 2026, on T

$BDRXMed

100 people have joined a trial for an inherited condition that causes colon polyps.

Biodexa Pharmaceuticals (BDRX) has enrolled 100 patients in its Phase 3 trial for eRapa, a treatment for Familial Adenomatous Polyposis (FAP). The trial, called Serenta, is recruiting at 29 sites in the US and Europe, with two more in Canada to start soon. The company expects a futility analysis early next year and database lock by the end of next year, earlier than initially anticipated.

$MIRMHighAI 9/10

Mirum Pharmaceuticals: Phase 3 EXPAND shows maralixibat meets primary endpoint, plans 1H 2027 sNDA

Mirum Pharmaceuticals reported that its drug maralixibat met the primary endpoint in the Phase 3 EXPAND trial, showing significant improvement in cholestatic pruritus. All secondary endpoints were also met, including reductions in serum bile acids. The company plans to submit a U.S. supplemental NDA in the first half of 2027. According to the company, safety data were consistent with prior experience.

$YRDLow

Yiren Digital appoints Na Mei as acting CEO (YRD:NYSE)

Yiren Digital (YRD) appointed Na Mei as acting CEO, effective October 13, 2026, following the investigation of CEO Ning Tang by authorities. The company's controlling affiliates are also involved in the probe. This leadership change may impact investor confidence and operations. According to Yiren Digital, Tang was placed under criminal measures.